Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2021-10-20 Regulatory Filings
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
지정자문인선임계약의체결
Regulatory Filings Classification · 100% confidence The document is a short, structured announcement regarding the appointment of a new designated advisor (Hana Financial Investment) following the termination of a previous contract with NH Investment & Securities. It does not constitute a full financial report or a major corporate event like an M&A or share issuance, but rather a regulatory disclosure of a corporate administrative change. Given the nature of the announcement, it fits best under the general regulatory filing category.
2021-10-20 Korean
전환가액의조정(제1회차)
Capital/Financing Update Classification · 100% confidence The document is an official notice regarding the adjustment of the conversion price of convertible bonds (1st series) for Ensol Biosciences due to a decline in market price. This type of filing, which details changes to capital structure instruments like convertible bonds, falls under the category of Capital/Financing Update.
2021-08-17 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding changes of Tiger Asset Management in Ensol Biosciences. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2021-08-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details a change in shareholding percentage by Yuhan Corporation in Ensol Biosciences. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2021-06-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when an insider or major shareholder changes their stake in a company. This specific document details a change in shareholding by Yuhan Corporation in Ensol Biosciences. This falls under the category of 'Director's Dealing' (DIRS) as it reports insider/major shareholder transactions.
2021-06-14 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 95% confidence The document is a short, structured announcement detailing the results of an Investor Relations (IR) event held by Ensol Biosciences. It lists the date, location, attendees, and agenda of the meeting. Since it is a brief notification of an event that has occurred rather than the full presentation deck itself, and it serves as a regulatory disclosure of the event's outcome, it fits the definition of a Regulatory Filing (RNS) or a report publication announcement. Given the specific nature of the disclosure regarding an IR event, RNS is the most appropriate classification.
2021-05-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.